223 related articles for article (PubMed ID: 35588011)
1. Treatment of unresectable intrahepatic cholangiocarcinoma using transarterial chemoembolisation with irinotecan-eluting beads: analysis of efficacy and safety.
Liu D; Wang J; Ma Z; Zhang N; Zhao Y; Yang X; Wen Z; Xie H
Cardiovasc Intervent Radiol; 2022 Aug; 45(8):1092-1101. PubMed ID: 35588011
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis.
Yang XG; Sun YY; Li DS; Xu GH; Huang XQ
Front Immunol; 2022; 13():940009. PubMed ID: 35874708
[TBL] [Abstract][Full Text] [Related]
3. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy.
Kuhlmann JB; Euringer W; Spangenberg HC; Breidert M; Blum HE; Harder J; Fischer R
Eur J Gastroenterol Hepatol; 2012 Apr; 24(4):437-43. PubMed ID: 22261548
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of efficacy and safety of transarterial chemoembolization with CalliSpheres and conventional transarterial chemoembolization in treating unresectable intrahepatic cholangiocarcinoma patients.
Sun T; Zhang W; Chen L; Ren Y; Liu Y; Zheng C
J Cancer; 2022; 13(4):1282-1288. PubMed ID: 35281867
[No Abstract] [Full Text] [Related]
5. Irinotecan eluting beads-transarterial chemoembolization using Callispheres® microspheres is an effective and safe approach in treating unresectable colorectal cancer liver metastases.
Zhao G; Liu S; Zhang Y; Zhao T; Wang R; Bian J; Wu J; Zhou J
Ir J Med Sci; 2022 Jun; 191(3):1139-1145. PubMed ID: 34264426
[TBL] [Abstract][Full Text] [Related]
6. Drug-eluting beads transarterial chemoembolization with CalliSpheres microspheres for treatment of unresectable intrahepatic cholangiocarcinoma.
Zhou TY; Zhou GH; Zhang YL; Nie CH; Zhu TY; Wang HL; Chen SQ; Wang BQ; Yu ZN; Wu LM; Zheng SS; Sun JH
J Cancer; 2020; 11(15):4534-4541. PubMed ID: 32489470
[No Abstract] [Full Text] [Related]
7. DEB-TACE with irinotecan
Wang J; Xue Y; Liu R; Wen Z; Ma Z; Yang X; Yu L; Yang B; Xie H
Front Bioeng Biotechnol; 2022; 10():1112500. PubMed ID: 36714623
[No Abstract] [Full Text] [Related]
8. A retrospective pilot study of transarterial chemoembolisation using camrelizumab-eluting Callisphere beads for unresectable hepatocellular carcinoma.
Shi X; Wang Y; Ren J; Han X; Bi Y
BMC Cancer; 2023 Nov; 23(1):1144. PubMed ID: 38001447
[TBL] [Abstract][Full Text] [Related]
9. Conventional and drug-eluting beads transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a systematic review and pooled analysis.
He M; Jiang N; Yin X; Xu A; Mu K
J Cancer Res Clin Oncol; 2023 Jan; 149(1):531-540. PubMed ID: 36402872
[TBL] [Abstract][Full Text] [Related]
10. Systemic chemotherapy plus transarterial chemoembolization versus systemic chemotherapy alone for unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study.
Jiang N; Zhang Z; Yin X; Qiu H; Yan W; Hao Y; Yang W; Li H; Xu A; Mu K
Radiol Med; 2024 Apr; 129(4):631-642. PubMed ID: 38355907
[TBL] [Abstract][Full Text] [Related]
11. The Comprehensive Analysis of Efficacy and Safety of CalliSpheres
Peng Z; Cao G; Hou Q; Li L; Ying S; Sun J; Zhou G; Zhou J; Zhang X; Ji W; Yu Z; Li T; Zhu D; Hu W; Ji J; Du H; Shi C; Guo X; Fang J; Han J; Gu W; Xie X; Sun Z; Xu H; Wu X; Hu T; Huang J; Hu H; Zheng J; Luo J; Chen Y; Yu W; Shao G
Oncol Res; 2020 May; 28(3):249-271. PubMed ID: 31856933
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma.
Bi Y; Shi X; Ren J; Yi M; Han X; Song M
BMC Gastroenterol; 2021 May; 21(1):231. PubMed ID: 34020608
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma.
Zhang N; Yu BR; Wang YX; Zhao YM; Zhou JM; Wang M; Wang LR; Lin ZH; Zhang T; Wang L
J Dig Dis; 2022 Aug; 23(8-9):535-545. PubMed ID: 36148493
[TBL] [Abstract][Full Text] [Related]
14. Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients.
Peng N; Mao L; Tao Y; Xiao K; Yuan G; He S
World J Surg Oncol; 2022 Aug; 20(1):254. PubMed ID: 35941634
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients.
Wang Z; Mu K; Lv Y; Zhao L; Li B; Hao Y; Wang N
Ir J Med Sci; 2022 Dec; 191(6):2493-2499. PubMed ID: 35064533
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of raltitrexed-eluting CalliSpheres
Sun Z; Jiao D; Fang Y; Liu Y; Xu K; Zhang C; Huang Y; Han X
Ther Adv Med Oncol; 2024; 16():17588359241229661. PubMed ID: 38362379
[TBL] [Abstract][Full Text] [Related]
17. Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads.
Bi Y; Shi X; Ren J; Yi M; Han X
Sci Rep; 2022 May; 12(1):8136. PubMed ID: 35581365
[TBL] [Abstract][Full Text] [Related]
18. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
[TBL] [Abstract][Full Text] [Related]
19. Drug-eluting beads transarterial chemoembolization by CalliSpheres is effective and well tolerated in treating intrahepatic cholangiocarcinoma patients: A preliminary result from CTILC study.
Luo J; Zheng J; Shi C; Fang J; Peng Z; Huang J; Sun J; Zhou G; Li T; Zhu D; Xu H; Hou Q; Ying S; Sun Z; Du H; Xie X; Cao G; Ji W; Han J; Gu W; Guo X; Shao G; Yu Z; Zhou J; Yu W; Zhang X; Li L; Hu H; Hu T; Wu X; Chen Y; Ji J; Hu W
Medicine (Baltimore); 2020 Mar; 99(12):e19276. PubMed ID: 32195932
[TBL] [Abstract][Full Text] [Related]
20. Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma.
Yuan P; Song J; Wang F; Zhu G; Chen B
Invest New Drugs; 2022 Oct; 40(5):1125-1132. PubMed ID: 35793038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
